Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalDRTS -2.77%28 Market Cap is $1,175.14 Mil as of Jul. 23, 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,423 Biotechnology companies, Alpha Tau Medical ranks better than 82.01% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alpha Tau Medical's share price for the quarter that ended in Mar. 2026 was $7.07. Alpha Tau Medical's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 90.18 Mil. Therefore, Alpha Tau Medical's market cap for the quarter that ended in Mar. 2026 was $637.54 Mil.
Alpha Tau Medical's quarterly market cap
increased
from Sep. 2025 ($384.54 Mil) to Dec. 2025 ($435.65 Mil) and
increased
from Dec. 2025 ($435.65 Mil) to Mar. 2026 ($637.54 Mil).
Alpha Tau Medical's annual market cap
increased
from Dec. 2023 ($209.71 Mil) to Dec. 2024 ($218.18 Mil) and
increased
from Dec. 2024 ($218.18 Mil) to Dec. 2025 ($435.65 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alpha Tau Medical's Enterprise Value for Today is $1,113.06 Mil.
Alpha Tau Medical (NAS:DRTS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alpha Tau Medical Market Cap Related Terms
Alpha Tau Medical Market Cap Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Tau Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Market Cap distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alpha Tau Medical's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTS) has a Market Cap of $1,175.14 Mil as of Jul. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #256 out of 1423 companies in the Biotechnology industry, placing it in the top 18%.
Is Alpha Tau Medical's Market Cap too high?
Alpha Tau Medical's current Market Cap is $1,175.14 Mil. The Biotechnology industry median Market Cap is 112.15. Alpha Tau Medical's value of $1,175.14 Mil is 947.8% above this industry median. Based on the distribution chart, Alpha Tau Medical ranks #256 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Market Cap compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #256 out of 1423 companies for Market Cap. This places Alpha Tau Medical in the top 18% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.15. Alpha Tau Medical's value of $1,175.14 Mil is 947.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.15, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Tau Medical's current Market Cap of $1,175.14 Mil is 947.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alpha Tau Medical and its competitors. For the Biotechnology industry, the median Market Cap is 112.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current Market Cap is $1,175.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Market Cap of $1,175.14 Mil. The current Market Cap is $1,175.14 Mil and 947.8% above the Biotechnology industry median of 112.15. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Market Cap is $1,175.14 Mil as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
